{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Expansion", "query": { "intervention": "Monoclonal antibody - Dose Expansion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 494, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Expansion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T10:54:19.929Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01629758", "title": "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms by Site" ], "interventions": [ { "name": "Denenicokin", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-06", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629758" }, { "nct_id": "NCT03834948", "title": "AO-176 in Multiple Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "AO-176", "type": "DRUG" }, { "name": "AO-176 + Paclitaxel", "type": "DRUG" }, { "name": "AO-176 + Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arch Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2019-02-04", "completion_date": "2023-02-15", "has_results": false, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834948" }, { "nct_id": "NCT01061749", "title": "Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2009-11", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2016-01-25", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061749" }, { "nct_id": "NCT02671435", "title": "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Monalizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2016-02-22", "completion_date": "2027-07-30", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02671435" }, { "nct_id": "NCT07024784", "title": "A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gynecologic Cancers", "Platinum-Sensitive Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer (PSOC)" ], "interventions": [ { "name": "IMGN151", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 377, "start_date": "2025-07-30", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 8, "location_summary": "Teaneck, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 5 more", "locations": [ { "city": "Teaneck", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Portland", "state": "Oregon" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT07024784" }, { "nct_id": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2 Positive Solid Tumors", "HER2 Amplification", "Colorectal Cancer" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2024-05-30", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 3, "location_summary": "Plantation, Florida • St Louis, Missouri • Fairfax, Virginia", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06328738" }, { "nct_id": "NCT05087992", "title": "A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer, Metastatic" ], "interventions": [ { "name": "BI 905711", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-11-24", "completion_date": "2023-11-14", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05087992" }, { "nct_id": "NCT07818018", "title": "A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Advanced Esophageal Cancer", "Gastric Cancer", "Advanced Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "Intratumoral 2141-V11", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Fluoropyrimidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-04", "completion_date": "2029-09-04", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07818018" }, { "nct_id": "NCT04678908", "title": "A Study of Injection HB0025 in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor, Subjects" ], "interventions": [ { "name": "HB0025", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Huabo Biopharm Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2021-03-10", "completion_date": "2024-05-23", "has_results": false, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678908" }, { "nct_id": "NCT02526017", "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Head and Neck Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Malignant Glioma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Cabiralizumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Five Prime Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2015-09-08", "completion_date": "2019-11-18", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-09-28T10:54:19.929Z", "location_count": 39, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02526017" } ] }